UK Kidney Association Guideline Sets Anticoagulation Framework for AF in Advanced CKD and Dialysis
This UKKA guideline, endorsed by the British Cardiovascular Society, gives renal pharmacists graded guidance on DOAC versus VKA selection, Cockcroft-Gault dosing, monitoring, and the option of no anticoagulation in CKD stage 4, stage 5 and dialysis.
📅 Journal publication: Aug 19, 2026·Last updated: Nov 18, 2026
Managing AF in CKD patients is challenging due to bleeding risks.
Patients with advanced chronic kidney disease (CKD) are at high risk for both thromboembolic events and bleeding when managing atrial fibrillation (AF). New UK Kidney Association guidelines provide best-practice guidance for anticoagulation in CKD patients with AF, addressing the use of direct oral anticoagulants (DOACs) and non-anticoagulation options. The guidelines clarify decision-making for anticoagulation in this challenging population, though limitations exist due to the exclusion of patients with advanced CKD from major trials. New guidelines guide anticoagulation decisions in advanced CKD patients with AF.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Parker K, Power A, Buka R, Davies M, Gauci MA, Hancock A, Hartemink J, Mitchell A, Thomas H, Tsang JY, Tseng I, Turley A, Lip GYH, guideline authors
Citation:Parker K, Power A, Buka R, et al. Anticoagulation for atrial fibrillation in adults with advanced kidney disease: UK kidney association clinical practice guideline. BMC nephrology. 2026;27(1). doi:10.1186/s12882-026-05270-9